Q5119Inj ruxience, 10 mg

Published CMS Medicare Part B payment-limit context for Q5119, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.

CMS payment limit

$16.16

per 10 MG · Medicare Part B

Up 18.1%from $13.686 in 2026-Q2

Current quarter: 2026-Q3FinalEffective July 1, 2026
Billing unit: 10 MG

Payment limit over time

$29.8855$11.2295

2024-Q4: $22.437; 2025-Q1: $23.589; 2025-Q2: $24.943; 2025-Q3: $26.503; 2025-Q4: $27.845; 2026-Q1: $13.27; 2026-Q2: $13.686; 2026-Q3: $16.16

No current FDA shortage matchThe latest completed FDA data has no affected record matching the Rituximab ingredient family (FDA data as of August 20, 2026).

Email me when FDA shortage status changes

Ruxience

Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.

Other Rituximab presentations

3 other CMS codes

Source-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.

Swipe to see all columns

HCPCS	CMS description	Current quarter 2026-Q3	Prior quarter 2026-Q2	Change
J9312	Inj., rituximab, 10 mg	$73.278 per 10 MG	$74.158 per 10 MG	Down 1.2%
Q5115	Inj truxima 10 mg	$34.563 per 10 MG	$31.278 per 10 MG	Up 10.5%
Q5123	Inj. riabni, 10 mg	$18.533 per 10 MG	$20.257 per 10 MG	Down 8.5%

Email me when a new presentation appears

Put another code on your radar.

Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.

Explore CMS codes